Flemish digital health startup Koios Care is working toward an AI that's trained to identify early signals of brain deterioration from a patient's everyday activity.
The Antwerp-HQed company initially plans to address Parkinson's disease having recently clinched €350,000 in pre-seed funds from the health tech investor Lumiares.
Founders Konstantinos Kyritsis and Dimitris Iakovakis started on this path six years ago in the hope of finding novel means to identify Parkinson's faster.
They're supported by clinical researchers led by CHU de Liege professor of neurology Gaëtan Garraux, and further assisted by Flemish health tech entrepreneurs Gregor Strobbe, Jurgen Van Broeck and Jean-Briac Prévost.
The managing director of Belgian biotech player Biogen, Kris Schellens, is also assisting giving the founders the benefit of his health tech expertise.
Koios's six-year research programme has already resulted in potential digital biomarkers for early phases of Parkinson's, using evidence from passive datasets.
The startup proposes to use this data to launch early Parkinson's detection digital health products, as well as enabling better monitoring of disease progression and quality of life metrics.
Konstantinos Kyritsis, appointed CEO of Koios Care, commented: "We are thrilled to have the support of Lumiares as we continue to advance our product and navigate the path towards the market.
"Koios Care enables neurologists and pharmaceutical companies to see new forms of data and patterns from patients’ daily living."
Lumiares managing partner Filip Vandamme added: "We are excited to partner with Koios Care and support their innovative approach to enhance clinical development for neurodegenerative diseases.
"We believe in the potential of their technology to make a real impact in the field of healthcare, and we are confident in their ability to continue to develop and bring their solutions to market."